NF-kappaB-IN-20 is an orally bioavailable inhibitor of NF-kappaB. By binding directly to the Keap1 protein, NF-kappaB-IN-20 activates the Keap1/Nrf2/HO-1 antioxidant pathway and concurrently inhibits the NF-kappaB inflammatory pathway, working synergistically to reduce oxidative stress and inflammation. Additionally, NF-kappaB-IN-20 M11 suppresses the expression of IL-6, IL-1beta, and TNF-alpha, significantly decreases ROS levels, and restores mitochondrial membrane potential. This compound is applicable in studies of acute lung injury (ALI).
Target:
Nrf2|||NF-kappaB|||ROS|||TNF|||Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
